Eight Sleep Raises $50 Million to Shift Focus to Predictive AI Health Platform

Eight Sleep, a technology firm based in New York specializing in sleep innovation, has finalized a $50 million funding round, which places its valuation at $1.5 billion, according to recent company announcements led by Tether Investments. This capital infusion is designated to support the company's strategic transition from offering reactive sleep optimization solutions to developing a fully predictive, Artificial Intelligence-driven health platform.

The foundation of Eight Sleep’s product remains the Pod system, which utilizes embedded biometric sensors within a mattress cover to monitor physiological signals such as heart rate and respiratory rate. The system then adjusts the sleeping environment’s temperature reactively to facilitate optimal rest. This evolution signifies a move within digital health beyond basic sleep scoring toward establishing the bedroom as a site for continuous health monitoring.

Central to this new operational phase is the development of a sophisticated AI agent designed to anticipate and preempt sleep disturbances based on user-specific patterns. This predictive model is currently being trained using a proprietary dataset that includes over one billion hours of global sleep data collected from users in more than 35 countries. Early pilot programs utilizing this predictive AI showed that nearly half of the participants subsequently modified their activity timing, caffeine intake, or sleep schedules based on the platform’s proactive guidance.

Eight Sleep is also pursuing clearance from the Food and Drug Administration (FDA) for specific features, particularly those intended to detect and mitigate sleep apnea. Securing this clearance would reclassify the Pod from a consumer wellness device to a regulated medical intervention tool capable of passive nightly screening. This regulatory pursuit aligns with projections for the global AI-powered sleep technology market, which is anticipated to grow from $13.6 billion in 2025 to $47.7 billion by 2035.

The company has also demonstrated clinical efficacy in targeted health areas. Two separate peer-reviewed studies validated that the Pod system reduced the frequency of menopausal hot flashes by an average of 56% after one week of use among 98 peri- and post-menopausal women in a 14-night protocol. This non-pharmacological intervention was also linked to restoring the body’s natural circadian temperature rhythm, which is associated with improved cardiovascular recovery markers. Co-founder and CEO Matteo Franceschetti stated that the company, which achieved free-cash-flow positivity in 2025, will use this investment to expand its intelligence capabilities across personal health dimensions. The partnership with Tether Investments includes leveraging Tether’s QVAC Health architecture to process sensitive biometric data locally on the device, emphasizing user privacy and offline functionality.